Compare Deutsche Bank AG (DB) vs DexCom, Inc. (DXCM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deutsche Bank AG vs DexCom, Inc. — how do they compare? Deutsche Bank AG trades at $33.69 (market cap $62.42B), while DexCom, Inc. trades at $84.14 (market cap $31.86B). The key difference: Deutsche Bank AG is the larger of the two by market cap, and Deutsche Bank AG pays a 3.46% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Deutsche Bank AG for 80 Days and DexCom, Inc. for 62 Days on average.
| DB | DXCM | |
|---|---|---|
Market Cap | $62.42B | $31.86B |
Volume | 2,918,760 | 3,607,070 |
Sector | Financials | Health |
52-Week High | $41.56 | $92.34 |
52-Week Low | $28.37 | $54.84 |
Typical Hold Time | 80 Days | 62 Days |
Enterprise Value | $77.06B | $31.32B |
Dividend Yield | 3.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Deutsche Bank (DB) trades at $33.58, showing minimal daily movement (+0.09%). The stock presents mixed signals with bearish technical indicators but attractive valuation metrics including a P/E of 9.09 and P/B of 0.71. Recent earnings show volatility with a Q2 2026 miss but strong Q1 2026 beat. The company demonstrates improved financial health with 2025 net cash flow of $7.61B and rising revenue trends from $30.0B in 2024 to $32.1B in 2025.
DB offers value investment potential with below-market valuations and positive cash flow generation, though technical weakness and mixed analyst sentiment (21% buy, 58% hold) suggest cautious optimism. Key risks include investment banking revenue volatility and significant workforce retirement challenges. The path to 2028 targets depends on wealth management growth and cost control execution.
DexCom (DXCM) trades at $84.03, down 0.32% on the day, with strong fundamental performance including three consecutive quarterly EPS beats and robust 20.12% net income margin. The stock shows bearish technical signals with price near pivot point support at $84, while analyst consensus remains overwhelmingly positive with 81% buy ratings and $95.07 price target representing 13% upside potential. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
DXCM presents a compelling growth story with expanding profit margins and consistent earnings outperformance, though technical weakness and premium valuation create near-term headwinds. The company's leadership in continuous glucose monitoring and Type 2 diabetes market expansion provide long-term catalysts, while competition and reimbursement risks require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Deutsche Bank AG
In July 2019, Deutsche Bank announced another restructuring plan hoping to revitalize revenue, reduce costs, and return to profitability. The largest moving pieces of the new plan is the full exit of global equity sales & trading, the scaling back of its fixed income business, as well as 18,000 FTE reductions until 2022. The remaining core business segments include private banking, corporate banking, asset management, and investment banking.
Read more on DB →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
